**Table S3: Study retention/completion of vaccine studies.**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **RECRUITMENT** | FV-naïvea | | FV-experienced | |
| White | 57.1% | | 50% | |
| African American | 39.3% | | 43.1% | |
| Non-white/AA races/ethnicities | 4.6% | | 3.4% | |
| Males | 52.4% | | 50% | |
| Median age | 29.3 | | 30 | |
| **RETENTION** | FV-naïvea | | FV-experienced | |
| Study completion | 62/84 (74%) | | 48/58 (83%) | |
| *By treatment* | TV003 | PLACEBO | TV003 | PLACEBO |
| Dose 1 | 60 | 24 | 41 | 17 |
| Dose 2 | 44 (73%) | 18 (75%) | 33 (80%) | 15 (88%) |
| Study completion (safety) | 44 (73%) | 18 (75%) | 33 (80%) | 15 (100%) |
| Study completion (PRNT) | 44 (73%) | 18 (75%) | 33 (80%) | 15 (88%) |

aData for flavivirus-naive study subjects are from ref. [[19](#_ENREF_19)], and include both cohorts (CIR279 and CIR268) from that study.